KalVista Pharmaceuticals Inc (nasdaq:KALV) Share Price

Company Profile

Business description
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Contact
55 Cambridge Parkway
Suite 901 East
CambridgeMA02142
USA
T: +1 857 999-0075
E: [email protected]
https://www.kalvista.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2026
Employees
270

Recommended

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.

Malik Ahmed Khan, CFA | 08 January 2026

Wagering continues to be challenged in Australia.

Angus Hewitt, CFA | 08 January 2026

Rising inflation is the fly in the ointment.

Simonelle Mody | 08 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,045.90	27.80	-0.31%
CAC 40	8,362.09	118.63	1.44%
DAX 40	25,261.64	134.18	0.53%
Dow JONES (US)	49,504.07	237.96	0.48%
FTSE 100	10,124.60	79.91	0.80%
HKSE	26,231.79	82.48	0.32%
NASDAQ	23,671.35	191.33	0.81%
Nikkei 225	51,939.89	822.63	1.61%
NZX 50 Index	13,696.25	20.61	-0.15%
S&P 500	6,966.28	44.82	0.65%
S&P/ASX 200	8,717.80	29.10	-0.33%
SSE Composite Index	4,120.43	37.45	0.92%